Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)

Summary

The goal of this study is to see whether or not a strategic planning process is able to introduce and sustain improvements in the working relationship between probation/parole departments and community-based addiction treatment agencies that provide medication assisted therapy (MAT) for individuals with opioid or alcohol dependence. In addition, this study seeks to improve probation/parole agency personnel's knowledge and perceptions about MAT, and increase the number of appropriate referrals to community treatment agencies that provide MAT. There are three phases to this study. Phase 1 includes a pilot study to determine the quality and availability of client level records and the collection of baseline data (the pilot study protocol was previously submitted to TMH IRB). Phase 2 will consist of a Knowledge, Perceptions and Information (KPI) intervention during which probation/parole agencies will undergo training to increase knowledge about the effectiveness of MAT, and complete a post training assessment to evaluate the effectiveness of the KPI intervention. During Phase 3, probation/parole agencies will be randomly assigned to a 12-month Organizational Linkage Intervention (OLI) condition or to control (no further intervention). Agencies assigned to the OLI will establish a Pharmacotherapy Exchange Council (PEC) that consists of staff from both the probation/parole and community treatment agencies. The PEC will undergo a strategic planning process to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole.

Conditions

• Opioid-Related Disorders
• Alcohol-Related Disorders

Interventions

OTHER

KPI training only

See comparison arm description.

OTHER

KPI plus OLI

See experimental arm description.

Sponsors & Collaborators

• Arizona State University

  collaborator OTHER

• Friends Research Institute, Inc.

  collaborator OTHER

• National Development and Research Institutes, Inc.

  collaborator OTHER

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Temple University

  collaborator OTHER

• Texas Christian University

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• University of Connecticut

  collaborator OTHER

• University of Delaware

  collaborator OTHER

• University of Kentucky

  collaborator OTHER

• University of Puerto Rico

  collaborator OTHER

• Rhode Island Hospital

  lead OTHER

Principal Investigators

• Peter D Friedmann, MD, MPH · Rhode Island Hospital

Study Design

Allocation

RANDOMIZED

Masking

NONE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-10-31

Primary Completion

2013-09-30

Completion

2013-09-30